October 9, 2002

Neurochem announces appointment of two new Board Members, Mr. Ronald M. Nordmann and Mr. Peter Kruyt.

Neurochem Inc. (TSX : NRM) is pleased to announce the appointments of Mr. Ronald M. Nordmann, Co-President, Global Health Associates, LLC, and Mr. Peter Kruyt, Vice-President of Power Corporation of Canada. The new directors have been appointed to fill the vacancies created by the resignations of Dr. André Boulet and Mr. Richard Dole.

"Mr. Nordmann offers to the Company an extensive knowledge of the life sciences field and in-depth experience in both the analysis of pharmaceutical companies and financial markets. Mr. Kruyt brings strong management experience and proven financial expertise" said Neurochem's Chairman of the Board of Directors, Dr. Francesco Bellini, and Dr. Louis R. Lamontagne, President and CEO of Neurochem. "We are extremely happy to welcome the two new appointees to Neurochem's Board of Directors and we would like to express our sincere appreciation to Dr. André Boulet and Mr. Richard Dole for their significant contribution to Neurochem during their tenure."

Mr. Nordmann brings over 35 years experience in the capital markets and pharmaceutical field to Neurochem. He began his career as Manager of Marketing Research for Warner Lambert and then served as senior health-care analyst for some of Wall Street's leading american financiers including PaineWebber, Incorporated, Oppenheimer & Co., Inc. and Deerfield Management. He is a member of the Board of Directors of a number of pharmaceutical companies including Shire Pharmaceuticals Group plc and is also a member of the Board of Trustees of The Johns Hopkins University.

Mr. Kruyt has been closely involved in activities of Power Corporation of Canada since 1981 working initially with its Chairman and subsequently with a number of subsidiaries. He is also President of Power Technology Investment Corporation and a member of the board of directors of a number of corporations including La Presse, Picchio Pharma Inc and Adaltis Inc. He is Chairman of the Board of Power Pacific Corporation Limited of Hong Kong Vice-Chairman of the Canada China Business Council and a member of the Board of Governors of Concordia University in Montreal.

About Neurochem

Neurochem is an industry leader in the development of therapeutic drugs and diagnostic tools for central nervous system (CNS) and amyloid-related diseases associated with aging. The Company has to date advanced three drug candidates to clinical trials: Fibrillex™, for the life-threatening orphan disease, secondary amyloidosis in a pivotal Phase II/III clinical trial, Alzhemed™, for the treatment of Alzheimer's Disease advancing to Phase II clinical trials, and Cerebril™, for hemorrhagic stroke also advancing to Phase II clinical trials. The Company has built a strong product pipeline by developing a novel, proprietary series of compounds that inhibit the formation, deposition and toxic effects of amyloid fibrils within the body. Neurochem's overall therapeutic programs target CNS disorders including Alzheimer's disease, epileptic seizures caused by head trauma or acute brain injury, and hemorrhagic stroke (due to cerebral amyloid angiopathy), and other life-threatening diseases including systemic amyloidosis and amyloid-associated diabetes type II. (www.neurochem.com).

All of the statements contained in this news release, other than statements of fact which are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements.

For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com

275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501

Our site is best viewed with IE4+ at a resolution of 1024×768.
All contents copyright © 1998-2007 Neurochem Inc.
Terms, Conditions and Legal Notice.